分化簇分子CD24、CD44、CD47在乳腺癌中的研究进展
Research Progress of Differentiation Cluster Molecules CD24, CD44, CD47 in Breast Cancer
DOI: 10.12677/acm.2025.1582209, PDF,    科研立项经费支持
作者: 岳林皓, 张国强, 王晓红, 王秋雨, 贾中明*：滨州医学院附属医院乳腺外科，山东 滨州
关键词: CD24；CD44；CD47；乳腺癌；表达；耐药；CD24； CD44； CD47； Breast Cancer； Expression； Resistance to Drugs
摘要: 分化簇分子CD24、CD44和CD47在乳腺癌的发生、发展及预后中扮演着关键角色。CD24在三阴性乳腺癌中备受关注，其高表达与药物抵抗性及肿瘤进展密切相关，并被认为是潜在的免疫治疗靶点。CD44作为细胞表面黏附分子，调控细胞增殖、分化和迁移，在乳腺癌中与肿瘤侵袭性及预后密切相关。CD47则作为抗凋亡分子，影响肿瘤细胞存活和免疫反应，其高表达与免疫逃逸机制相关，靶向CD47的免疫疗法展现出显著治疗潜力。本文综述了CD24、CD44和CD47在乳腺癌中的表达特征、临床意义及作用机制，并探讨其作为治疗靶点的潜力，旨在为乳腺癌的诊断、预后评估和治疗提供新的方向和策略。
Abstract: The differentiation cluster molecules CD24, CD44 and CD47 play key roles in the occurrence, development and prognosis of breast cancer. CD24 has attracted much attention in triple-negative breast cancer. Its high expression is closely related to drug resistance and tumor progression, and is considered as a potential immunotherapy target. CD44, as a cell surface adhesion molecule, regulates cell proliferation, differentiation and migration, and is closely related to tumor invasion and prognosis in breast cancer. As an anti-apoptotic molecule, CD47 affects tumor cell survival and immune response, and its high expression is related to immune escape mechanisms. Immunotherapy targeting CD47 has shown significant therapeutic potential. This article reviews the expression characteristics, clinical significance and mechanism of CD24, CD44 and CD47 in breast cancer, and discusses their potential as therapeutic targets, aiming to provide new directions and strategies for the diagnosis, prognosis evaluation and treatment of breast cancer.
文章引用：岳林皓, 张国强, 王晓红, 王秋雨, 贾中明. 分化簇分子CD24、CD44、CD47在乳腺癌中的研究进展[J]. 临床医学进展, 2025, 15(8): 129-136. https://doi.org/10.12677/acm.2025.1582209

参考文献

[1] Lindberg, I., Saleh, A., Tutzauer, J., Gunnarsdottir, F.B., Rydén, L., Bergenfelz, C., et al. (2025) Prognostic Relevance of CD163+ Immune Cells in Patients with Metastatic Breast Cancer. Cancer Immunology, Immunotherapy, 74, Article No. 42. [Google Scholar] [CrossRef] [PubMed]
[2] Chang, M.C., Eslami, Z., Ennis, M. and Goodwin, P.J. (2021) Crown-Like Structures in Breast Adipose Tissue of Breast Cancer Patients: Associations with CD68 Expression, Obesity, Metabolic Factors and Prognosis. npj Breast Cancer, 7, Article No. 97. [Google Scholar] [CrossRef] [PubMed]
[3] Corachea, A.J.M., Ferrer, R.J.E., Ty, L.P.B., Aquino, L.A.C., Morta, M.T., Macalindong, S.S., et al. (2025) Lymphovascular Invasion Is Associated with Doxorubicin Resistance in Breast Cancer. Laboratory Investigation, 105, Article ID: 104115. [Google Scholar] [CrossRef] [PubMed]
[4] Noblejas-López, M.d.M., Baliu-Piqué, M., Nieto-Jiménez, C., Cimas, F.J., Morafraile, E.C., Pandiella, A., et al. (2021) Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation. International Journal of Molecular Sciences, 22, Article 3836. [Google Scholar] [CrossRef] [PubMed]
[5] Kaur, S., Reginauld, B., Razjooyan, S., Phi, T., Singh, S.P., Meyer, T.J., et al. (2024) Effects of a Humanized CD47 Antibody and Recombinant SIRPα Proteins on Triple Negative Breast Carcinoma Stem Cells. Frontiers in Cell and Developmental Biology, 12, Article 1356421. [Google Scholar] [CrossRef] [PubMed]
[6] Zhu, X., Yu, J., Ai, F., Wang, Y., Lv, W., Yu, G., et al. (2023) CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1. Breast Cancer: Targets and Therapy, 15, 967-984. [Google Scholar] [CrossRef] [PubMed]
[7] Wang, J., Zhang, H., Zhu, G., Zhao, L., Shi, J., Dai, Z., et al. (2024) STT3-Mediated Aberrant N-Glycosylation of CD24 Inhibits Paclitaxel Sensitivity in Triple-Negative Breast Cancer. Acta Pharmacologica Sinica, 46, 1097-1110. [Google Scholar] [CrossRef] [PubMed]
[8] Yang, P., Yu, F., Yao, Z., Ding, X., Xu, H. and Zhang, J. (2023) CD24 Is a Novel Target of Chimeric Antigen Receptor T Cells for the Treatment of Triple Negative Breast Cancer. Cancer Immunology, Immunotherapy, 72, 3191-3202. [Google Scholar] [CrossRef] [PubMed]
[9] Yang, Y., Li, J., Zhang, J., Wu, H., Yang, Y., Guo, H., et al. (2025) PPAB001, a Novel Bispecific Antibody against CD47 and CD24, Enhances Anti-PD-L1 Efficacy in Triple-Negative Breast Cancer via Reprogramming Tumor-Associated Macrophages Towards M1 Phenotype. International Immunopharmacology, 144, Article ID: 113740. [Google Scholar] [CrossRef] [PubMed]
[10] Zhou, M., Xie, P., Chen, L., et al. (2023) Correlation between the Expression of CD24 on Circulating Tumor Cells and Prognosis in Breast Cancer. American Journal of Translational Research, 15, 1941-1952.
[11] Wang, X., Cheng, K., Zhang, G., Jia, Z., Yu, Y., Guo, J., et al. (2020) Enrichment of CD44 in Exosomes from Breast Cancer Cells Treated with Doxorubicin Promotes Chemoresistance. Frontiers in Oncology, 10, Article 960. [Google Scholar] [CrossRef] [PubMed]
[12] Morath, I., Jung, C., Lévêque, R., Linfeng, C., Toillon, R., Warth, A., et al. (2018) Differential Recruitment of CD44 Isoforms by ERBB Ligands Reveals an Involvement of CD44 in Breast Cancer. Oncogene, 37, 1472-1484. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Z., Wang, Q., Wang, Q., Wang, Y. and Chen, J. (2017) Prognostic Significance of CD24 and CD44 in Breast Cancer: A Meta-Analysis. The International Journal of Biological Markers, 32, 75-82. [Google Scholar] [CrossRef] [PubMed]
[14] Sari, S., Özdemir, Ç. and Çilekar, M. (2022) The Relationship of Tumour-Associated Macrophages (CD68, CD163, CD11c) and Cancer Stem Cell (CD44) Markers with Prognostic Parameters in Breast Carcinomas. Polish Journal of Pathology, 73, 299-309. [Google Scholar] [CrossRef] [PubMed]
[15] Chen, Y., Klingen, T.A., Aas, H., Wik, E. and Akslen, L.A. (2023) CD47 and CD68 Expression in Breast Cancer Is Associated with Tumor‐Infiltrating Lymphocytes, Blood Vessel Invasion, Detection Mode, and Prognosis. The Journal of Pathology: Clinical Research, 9, 151-164. [Google Scholar] [CrossRef] [PubMed]
[16] Celepli, P., Karabulut, S., Bigat, İ., Celepli, S. and Hücümenoğlu, S. (2022) CD47 Expression and Tumor-Associated Immune Cells in Breast Cancer and Their Correlation with Molecular Subtypes and Prognostic Factors. Pathology—Research and Practice, 238, Article ID: 154107. [Google Scholar] [CrossRef] [PubMed]
[17] Chen, C., Wang, R., Chen, X., Hou, Y. and Jiang, J. (2022) Targeting CD47 as a Novel Immunotherapy for Breast Cancer. Frontiers in Oncology, 12, Article 924740. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, B., Shi, J., Shi, X., Xu, X., Gao, L., Li, S., et al. (2024) Development and Evaluation of a Human CD47/HER2 Bispecific Antibody for Trastuzumab-Resistant Breast Cancer Immunotherapy. Drug Resistance Updates, 74, Article ID: 101068. [Google Scholar] [CrossRef] [PubMed]
[19] Li, L., Gong, Y., Tang, J., Yan, C., Li, L., Peng, W., et al. (2022) ZBTB28 Inhibits Breast Cancer by Activating IFNAR and Dual Blocking CD24 and CD47 to Enhance Macrophages Phagocytosis. Cellular and Molecular Life Sciences, 79, Article No. 83. [Google Scholar] [CrossRef] [PubMed]
[20] Cheng, Y., Lin, L., Li, X., Lu, A., Hou, C., Wu, Q., et al. (2021) ADAM10 Is Involved in the Oncogenic Process and Chemo-Resistance of Triple-Negative Breast Cancer via Regulating Notch1 Signaling Pathway, CD44 and PrPc. Cancer Cell International, 21, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
[21] Bian, Y., Lin, T., Jakos, T., Xiao, X. and Zhu, J. (2022) The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer. Biomedicines, 10, Article 1843. [Google Scholar] [CrossRef] [PubMed]
[22] Huth, H.W., Castro-Gomes, T., de Goes, A.M. and Ropert, C. (2021) Translocation of Intracellular CD24 Constitutes a Triggering Event for Drug Resistance in Breast Cancer. Scientific Reports, 11, Article No. 17077. [Google Scholar] [CrossRef] [PubMed]
[23] Qu, X., Li, Q., Tu, S., Yang, X. and Wen, W. (2021) ELF5 Inhibits the Proliferation and Invasion of Breast Cancer Cells by Regulating CD24. Molecular Biology Reports, 48, 5023-5032. [Google Scholar] [CrossRef] [PubMed]
[24] Chantziou, A., Theodorakis, K., Polioudaki, H., de Bree, E., Kampa, M., Mavroudis, D., et al. (2021) Glycosylation Modulates Plasma Membrane Trafficking of CD24 in Breast Cancer Cells. International Journal of Molecular Sciences, 22, Article 8165. [Google Scholar] [CrossRef] [PubMed]
[25] Ye, Z., Dong, X., Chen, H., Gu, D. and Qiu, Z. (2021) Circular RNA CDR1as-Induced Autophagy Regulates the Proliferation and Migration of CD44+/CD24- Phenotype Breast Cancer Stem Cells in Vitro. All Life, 14, 569-576. [Google Scholar] [CrossRef] 
[26] Chantaraamporn, J., Pothipan, P., Sakulterdkiat, T., Khiankaew, B., Lumkul, L., Mutapat, P., et al. (2024) CD47 and Calreticulin Expression in Breast Cancer Subtypes and Anti-CD47 Inhibitory Effects in Macrophage-Mediated Phagocytosis. Anticancer Research, 44, 4929-4940. [Google Scholar] [CrossRef] [PubMed]
[27] Qiao, X., Zhang, Y., Sun, L., Ma, Q., Yang, J., Ai, L., et al. (2021) Association of Human Breast Cancer CD44-/CD24- Cells with Delayed Distant Metastasis. eLife, 10, e65418. [Google Scholar] [CrossRef] [PubMed]
[28] Liu, C., Zhang, Y., Gao, J., Zhang, Q., Sun, L., Ma, Q., et al. (2023) A Highly Potent Small-Molecule Antagonist of Exportin-1 Selectively Eliminates CD44+CD24- Enriched Breast Cancer Stem-Like Cells. Drug Resistance Updates, 66, Article ID: 100903. [Google Scholar] [CrossRef] [PubMed]
[29] Sethi, A., Mishra, S., Upadhyay, V., Dubey, P., Siddiqui, S., Singh, A.K., et al. (2024) USP10 Deubiquitinates and Stabilizes CD44 Leading to Enhanced Breast Cancer Cell Proliferation, Stemness and Metastasis. Biochemical Journal, 481, 1877-1900. [Google Scholar] [CrossRef] [PubMed]
[30] Yan, H., Huang, W., Chen, C., Zhang, X., Zhu, K. and Yuan, J. (2023) MiR-133a/CD47 Axis Is a Novel Prognostic Biomarker to Promote Triple Negative Breast Cancer Progression. Pathology—Research and Practice, 244, Article ID: 154400. [Google Scholar] [CrossRef] [PubMed]
[31] Abdoli Shadbad, M., Hosseinkhani, N., Asadzadeh, Z., Derakhshani, A., Karim Ahangar, N., Hemmat, N., et al. (2021) A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and the Road Ahead. Frontiers in Oncology, 11, Article 689839. [Google Scholar] [CrossRef] [PubMed]
[32] Guo, Q., Liu, Y., He, Y., Du, Y., Zhang, G., Yang, C., et al. (2021) CD44 Activation State Regulated by the CD44v10 Isoform Determines Breast Cancer Proliferation. Oncology Reports, 45, Article No. 7. [Google Scholar] [CrossRef] [PubMed]
[33] Vadhan, A., Hou, M., Vijayaraghavan, P., Wu, Y., Hu, S.C., Wang, Y., et al. (2022) CD44 Promotes Breast Cancer Metastasis through AKT-Mediated Downregulation of Nuclear FOXA2. Biomedicines, 10, Article 2488. [Google Scholar] [CrossRef] [PubMed]
[34] Martins Gama, J., Caetano Oliveira, R., Teixeira, P., Silva, F., Abrantes, C., Figueiredo, P., et al. (2023) An Immunohistochemical Study of Breast Cancer Brain Metastases: The Role of CD44 and AKT in the Prognosis. Applied Immunohistochemistry & Molecular Morphology, 31, 318-323. [Google Scholar] [CrossRef] [PubMed]
[35] Malla, R., Jyosthsna, K., Rani, G. and Purnachandra Nagaraju, G. (2024) CD44/PD-L1-Mediated Networks in Drug Resistance and Immune Evasion of Breast Cancer Stem Cells: Promising Targets of Natural Compounds. International Immunopharmacology, 138, Article ID: 112613. [Google Scholar] [CrossRef] [PubMed]
[36] Carvalho, A.M., Soares da Costa, D., Reis, R.L. and Pashkuleva, I. (2021) Influence of Hyaluronan Density on the Behavior of Breast Cancer Cells with Different CD44 Expression. Advanced Healthcare Materials, 11, e2101309. [Google Scholar] [CrossRef] [PubMed]
[37] Yüceer, R.O., Aydın, S., Gelir, I., Koc, T., Tuncer, E. and Ucar, M. (2025) Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer. Diagnostics, 15, Article 232. [Google Scholar] [CrossRef] [PubMed]
[38] Ahmed, M.S.U., Lord, B.D., Adu Addai, B., Singhal, S.K., Gardner, K., Salam, A.B., et al. (2023) Immune Profile of Exosomes in African American Breast Cancer Patients Is Mediated by Kaiso/THBS1/CD47 Signaling. Cancers, 15, Article 2282. [Google Scholar] [CrossRef] [PubMed]
[39] Tong, S., Zhu, Y., Leng, Y., Wu, Y., Xiao, X., Zhao, W., et al. (2024) Restoration of miR-299-3p Promotes Macrophage Phagocytosis and Suppresses Malignant Phenotypes in Breast Cancer Carcinogenesis via Dual-Targeting CD47 and ABCE1. International Immunopharmacology, 130, Article ID: 111708. [Google Scholar] [CrossRef] [PubMed]
[40] Upton, R., Banuelos, A., Feng, D., Biswas, T., Kao, K., McKenna, K., et al. (2021) Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance. Proceedings of the National Academy of Sciences, 118, e2026849118. [Google Scholar] [CrossRef] [PubMed]
[41] Sun, Y., Liang, S., Li, T., Peng, C., Yang, Y., Lin, Y., et al. (2022) Prognostic Implications of Combined High Expression of CD47 and MCT1 in Breast Cancer: A Retrospective Study during a 10-Year Period. Translational Cancer Research, 11, 29-42. [Google Scholar] [CrossRef] [PubMed]
[42] Guo, L., Ke, H., Zhang, H., Zou, L., Yang, Q., Lu, X., et al. (2022) TDP43 Promotes Stemness of Breast Cancer Stem Cells through CD44 Variant Splicing Isoforms. Cell Death & Disease, 13, Article No. 428. [Google Scholar] [CrossRef] [PubMed]
[43] Gu, J., Chen, D., Li, Z., Yang, Y., Ma, Z. and Huang, G. (2022) Prognosis Assessment of CD44+/CD24− in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Archives of Gynecology and Obstetrics, 306, 1147-1160. [Google Scholar] [CrossRef] [PubMed]

为你推荐